Monoamine receptors and signal transduction mechanisms in suicide

Current Psychiatry Reviews

Volumn 2, Issue 1, 2006, Pages 51-75

  Pandey, Ghanshyam N ^a   Dwivedi, Yogesh ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Kinases; Monoamine receptors; Mood disorders; Signal transduction; Suicide; Transcription factors

Indexed keywords

ADENYLATE CYCLASE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FENFLURAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; HOMOVANILLIC ACID; LITHIUM SALT; MARCKS PROTEIN; MESSENGER RNA; NEUROLEPTIC AGENT; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C GAMMA; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

ADRENERGIC SYSTEM; AGGRESSION; ANXIETY DISORDER; AUTOPSY; CAUSE OF DEATH; DEPRESSION; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; HOPELESSNESS; HUMAN; MONOAMINERGIC SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SECOND MESSENGER; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT;

EID: 33745833987     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340006775101436     Document Type: Review

References (321)

1. Botsis AF, Soldatos CR, Stefanis CN. Suicide. Biopsychosocial Approaches. Elsevier, Amsterdam, 1997.
2. Moscicki EK, O'Carroll P, Rae DS, Locke BZ, Roy A, Regier DA. Suicide attempts in the Epidemiologic Catchment Area Study. Yale J Biol Med 1988; 61: 259-68.
3. Reducing Suicide, A National Imperative, Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE, editors, Committee on Pathophysiology and Prevention of Adolescent and Adult Suicide, Board on Neuroscience and Behavioral Health, Institute of Medicine of the National Academies, The National Academies Press, Washington, DC, 2002.
4. Minino AM, Smith BL. Deaths: preliminary data for 2000. Natl Vital Stat Rep 2001; 49: 1-40.
5. Conwell Y, Duberstein PR, Cox C, Herrmann JH, Forbes NT, Caine ED. Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry 1996; 153: 1001-8.
6. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: 205-28.
7. National Center for Health Statistics: Advance report of final mortality statistics, 1994. NCHS Monthly Vital Statistics Report 40 (suppl. 2): 1992
8. Moscicki EK. Identification of suicide risk factors using epidemiologic studies. Psychiatr Clin North Am 1977; 20: 499-517.
9. Lönqvist JK. Psychiatric aspects of suicidal behavior: Depression. Hawton K, van Heeringen K, Editors. The International Handbook of Suicide and Attempted Suicide (pp. 107-120). Chichester, UK: John Wiley and Sons.
10. Regier DA, Farmer ME, Rae DS, et al. One-month prevalence of mental disorders in the United States and sociodemographic characteristics: the Epidemiologic Catchment Area study. Acta Psychiatr Scand 1993; 88: 35-47.
11. Kessler R.C, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch Gen Psychiatry 1994; 51: 8-19.
12. Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 1997; 54:305-9.
13. Weissman MM, Klerman GL, Markowitz JS, Ouellette R. Suicidal ideation and suicide attempts in panic disorder and attacks. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med 1989; 321: 1209-14.
14. Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry 2000; 61 Suppl 5: 4-12; discussion 13-14.
15. Molnar BE, Berkman LF, Buka SL. Psychopathology, childhood sexual abuse and other childhood adversities: relative links to subsequent suicidal behaviour in the US. Psychol Med 2001; 31:965-977.
16. Caldwell CB, Gottesman II. Schizophrenia - a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav 1992; 22: 479-93.
17. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173:11-53.
18. APA (American Psychiatric Association). 1994. The Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC.
19. Hlady WG, Middaugh JP. Suicides in Alaska: firearms and alcohol. Am J Public Health 1988; 78:179-80.
20. May PA. Adolescent suicide in the West. Second Bi-Regional Adolescent Suicide Prevention Conference. Washington, DC: US DHHS, Health Resources and Services Administration, Maternal and Child Health Bureau, 1995.
21. Linnoila VM, Virkkunen M. Aggression, suicidality, and serotonin. J Clin Psychiatry 1992; 53:46-51.
22. Brent D, Kolko D, Wartella M, et al. Adolescent psychiatric inpatients' risk of suicide attempt at 6-month followup. J Am Acad Child Adolesc Psychiat 1993; 32: 95-105.
23. Brent DA, Baugher M, Bridge J, Chen T, Chiappetta L. Age- and sex-related risk factors for adolescent suicide. J Am Acad Child Adolesc Psychiatry. 1999; 38: 1497-505.
24. Westrin A. Stress system alterations and mood disorders in suicidal patients. Biomed Pharmacother 2000; 54: 142-5.
25. Beck AT, Steer RA, Beck JS, Newman CF. Hopelessness, depression, suicidal ideation, and clinical diagnosis of depression. Suicide Life Threat Behav 1993; 23: 139-45.
26. Welte JW, Abel EL, Wieczorek W. The role of alcohol in suicides in Erie County, NY, 1972-84. Public Health Rep 1988; 103: 648-52.
27. Brent DA, Kolko DJ, Allan MJ, Brown RV. Suicidality in affectively disordered adolescent inpatients. J Am Acad Child Adolesc Psychiatry 1990; 29: 586-93.
28. Weishaar ME, Beck AT.1990. Cognitive approaches to understanding and treating suicidal behavior. In: Blumenthal SJ, Kupfer DJ, Editors. Suicide Over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients. (pp.469-498). Washington, DC: American Psychiatric Press.
29. Pandey GN, Dwivedi Y, Pandey SC, Conley RC, Roberts RC, Tamminga CA. Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett 1997; 28: 111-4.
30. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Conley RR. Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study. Arch Gen Psychiatry 2004; 61: 685-93.
31. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999; 156: 181-9.
32. Apter A, Gothelf D, Orbach I, et al. Correlation of suicidal and violent behavior in different diagnostic categories in hospitalized adolescent patients. J Am Acad Child Adolesc Psychiatry 1995; 34: 912-18.
33. Berenson CK. Frequently missed diagnoses in adolescent psychiatry. Psychiatr Clin North Am 1998; 21: 917-26.
34. Black IB, Henry IA, Iversen LL. Transsynaptic regulation of growth and development of adrenergic neurones in a mouse sympathetic ganglion. Brain Res 1971; 34: 229-40.
35. Goldman-Rakic PS, Brown RM. Postnatal development of monoamine content and synthesis in the cerebral cortex of Rhesus monkeys. Brain Res Dev Brain Res 1982; 4: 339-49.
36. Emslie GJ, Rush J, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-37.
37. Paykel ES. Life stress, depression and attempted suicide 1976; 2:3-12.
38. Brown GL, Ebert MH, Goyer PF, et al. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am J Psychiatry 1982; 139: 741-6.
39. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983; 33: 2609-14.
40. Mann JJ. Psychobiologic predictors of suicide. J Clin Psychiatry 1987; 48 Suppl: 39-43.
41. Mann JJ, Marzuk PM, Arango V, McBride PA, Leon AC, Tierney H. Neurochemical studies of violent and nonviolent suicide. Psychopharmacol Bull 1989; 25: 407-13.
42. Coccaro EF, Siever LJ, Klar HM, et al. Central serotonin and impulsive aggression. Arch Gen Psychiatry 1989; 46: 587-99.
43. Mann JJ. Violence and aggression. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp. 1919-1928, 1995
44. Coryell W, Schlesser MA. Suicide and the dexamethasone suppression test in unipolar depression. Am J Psychiatry 1981; 138: 1120-1.
45. Targum SD, Rosen L, Capodanno AE. The dexamethasone suppression test in suicidal patients with unipolar depression. Am J Psychiatry 1983; 140: 877-9.
46. van Heeringen K, Audenaert K, Van de Wiele L, Verstraete A. Cortisol in violent suicidal behaviour: association with personality and monoaminergic activity. J Affect Disord 2000; 60: 181-9.
47. Coryell W, Schlesser M. The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001; 158: 748-53.
48. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987.
49. Asberg M, Traskman L, Thoren P. 5-HIAA in cerebrospinal fluid: a biochemical suicide predictor. Arch Gen Psychiatry 1976; 33: 1193-7.
50. Asberg M, Bertilsson L, Martensson B, Scalla-Tomba GP, Thoren P, Traskman-Bendz L. CSF monoamine metabolism in melancholia. Acta Psychiatr Scand 1984; 69: 201-19.
51. Agren H. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. Psychiatry Res 1980; 3: 211-24.
52. Van Praag HM. CSF, 5-HIAA and suicide in non-depressed schizophrenics. Lancet 1983; 2: 977-8.
53. Roy A, Pickar D, Linnoila M, Doran AR, Ninan P, Paul SM. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res 1985; 15: 281-92.
54. Van Praag HM. Depression, suicide and the metabolism of serotonin in the brain. J Affect Disord 1982; 4: 275-90.
55. Nordstrom P, Samuelsson M, Asberg M, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav 1994; 24: 1-9.
56. Tuomisto J, Tukiainen E. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature 1976; 262: 596.
57. Meltzer HY, Arora RC, Baber R, Tricou B.J. Serotonin uptake in blood platelets of psychiatric patients. Arch Gen Psychiatry 1981; 38: 1322-6.
58. Stanley M, Virgilio J, Gershon S. Tritiated impramine binding sites are decreased in the frontal cortex of suicides. Science 1982; 216: 1337-9.
59. Perry EK, Marshall EF, Blessed G, Tomlinson BE, Perry RH. Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry 1983; 142: 188-92.
60. Crow JT, Cross AJ, Cooper SJ, et al. Neurotransmitter receptors and monoamine metabolites in the brain of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 1984; 23: 1561-9.
61. Rausch JL, Janowsky DS, Risch SC, Huey LY. A kinetic analysis and replication of decreased platelet serotonin uptake in depressed patients. Psychiatry Res 1986; 19: 105-12.
62. 3H]Imipramine binding in the frontal cortex of suicides. Psychiatry Res 1989; 30: 125-35.
63. Lichtenberg P, Shapira B, Gillon D, et al. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res 1992; 43: 137-46.
64. Mann JJ, McBride PA, Brown RP, et al. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry 1992; 49:442-6.
65. Asnis GM, Eisenberg J, van Praag HM, Lemus CZ, Friedman JM, Miller AH. The neuroendocrine response to fenfluramine in depressives and normal controls. Biol Psychiatry 1988; 24: 117-20.
66. Cowen PJ. Serotonin receptor subtypes: neuroendocrine regulation in depression. Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A: 96A.
67. Maes M, D'Hondt P, Suy E, Minner B, Vandervorst C, Raus J. HPA-axis hormones and prolactin responses to dextrofenfluramine in depressed patients and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 781-90.
68. Meltzer HY, Umberkoman-Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. Arch Gen Psychiatry 1984; 41: 366-74.
69. Secunda SK, Cross CK, Koslow S, et al. Biochemistry and suicidal behavior in depressed patients. Biol Psychiatry 1986; 21: 756-67.
70. Traskman-Bendz L, Asberg M, Bertilsson L, Thoren P. CSF monoamine metabolites of depressed patients during illness and after recovery. Acta Psychiatr Scand 1984; 69: 333-42.
71. Ostroff R, Giller E, Bonese K, Ebersole E, Harkness L, Mason J. Neuroendocrine risk factors of suicidal behavior. Am J Psychiatry 1982; 139: 1323-5.
72. Prasad A. Neuroendocrine differences between violent and non-violent parasuicide. Abstracts of the Annual Meeting Collegium Internationale Neuropsychopharmacologium, Florence, Italy, 1984, pp. 64.
73. 2-binding sites in frontal cortex of suicide victims. Lancet 1983; i: 214-16.
74. Mann JJ, Stanley M, McBride PA, McEwen BS. Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43: 954-9.
75. McKeith IG, Marshall EF, Ferrier IN, et al. 5-HT receptor binding in postmortem brain from patients with affective disorders. J Affect Dis 1987; 13: 667-4.
76. Arora RC, Meltzer HY. Serotonergic measures in the brain of suicide victims: 5HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 1986; 146: 730-6.
77. Biegon A, Weizman A, Karp L, Ram A, Tiano S, Wolff M. Serotonin uptake in blood platelets and the dexamethasone suppression test in depressed patients. Serotonin 5-HT2 receptor binding on platelets - A peripheral marker for depression. Life Sci 1987; 41: 2485-92.
78. Arora RC, Meltzer HY. Increased serotonin-2 (5HT2) receptor-binding as measured by (3H)-lysergic acid diethylamide (3H-LSD) in the blood-platelets of depressed patients. Life Sci 1989; 44: 725-34.
79. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM. Platelet serotonin2 receptor binding sites in depression and suicide. Biol Psychiatry 1990; 28: 215-22.
80. Cowen PJ, Charig EM, Fraser S, Elliott JM. Platelet 5HT receptor binding during depressive illness and tricyclic antidepressant treatment. Affect Dis 1987; 13: 45-50.
81. 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm 1987; 70: 377-81.
82. DePaermentier F, Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain β-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 1990; 525: 71-77.
83. Ferrier IN, Perry EK. Post-mortem studies in affective disorder. Psychol Med 1992; 22: 835-8.
84. 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem 1994; 63: 256-65.
85. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997; 17: 8451-8.
86. Klimek V, Rajkowska G, Luker SN, et al. Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology 1999; 21: 69-81.
87. Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry 1981; 38: 1315-7.
88. 3H] imipramine binding label serotonin reuptake sites in brain and platelet? Life Sci 1981; 28: 2753-60.
89. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40: 288-95.
90. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp. 933-944, 1995
91. Mann JJ. Role of Serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999; (2 Suppl): 99S-105S.
92. Langer SZ, Javoy-Agid F, Raisman R, Briley M, Agid Y: Distribution of specific high-affinity binding sites for [3H]imipramine in human brain. J Neurochem 1981; 37: 267-71.
93. Gross-Isseroff R, Biegon A, Voet H, Weizman A. The suicide brain: a review of postmortem receptor/transporter binding studies. Neurosci Biobehav Rev 1998; 22: 653-61.
94. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res 2003; 37: 357-73.
95. Meyerson LR, Wennogle LP, Abel MS, et al. Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav 1982; 17: 159-63.
96. Owen F, Chambers DR, Cooper SJ, et al. Serotonergic mechanisms in brains of suicide victims. Brain Res 1986; 362: 185-8.
97. Gross-Isseroff R, Israeli M, Biegon A. Autoradiographic analysis of tritiated imipramine binding in the human brain postmortem: effects of suicide. Arch Gen Psychiatry 1989; 46: 237-41.
98. 3H] imipramine binding in brain samples from depressed suicides and controls: 5-HT uptake sites compared with sites defined by desmethylimipramine. J Affect Disord 1998; 47: 105-12.
99. 2 receptors in suicide victims. Biol Psychiatry 1994; 35: 457-63.
100. 3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology 1996; 14: 309-23.
101. Leake A, Fairbairn AF, McKeith IG, Ferrier IN. Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res 1991; 39: 155-65.
102. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 1993; 50: 810-8.
103. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8: 315-36.
104. Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 1995; 688: 121-33.
105. 3H]paroxetine, in antidepressant-free depressed suicides. Brain Res 1990; 562: 17-22.
106. 2 sites in cortex and amygdala. Brain Res 1993; 614: 37-44.
107. Little KY, McLaughlin DP, Ranc J, et al. Serotonin transporter binding sites and mRNA levels in depressed persons committing suicide. Biol Psychiatry 1997; 41: 1156-64.
108. Bligh-Glover W, Kolli TN, Shapiro-Kulnane L, et al. The serotonin transporter in the midbrain of suicide victims with major depression. Biol Psychiatry 2000; 47: 1015-24.
109. Pandey GN, Pandey SC, Dwivedi Y, Sharma RS, Janicak PG, Davis J.M. Platelet serotonin 2A receptors: a potential biological marker for suicidal behavior. Am J Psychiatry 1995; 152: 850-5.
110. Humphrey PPA, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993; 14: 233-6.
111. Teitler M, Herrick-Davis K. Multiple serotonin receptor subtypes: molecular cloning and functional expression. Crit Rev Neurobiol 1994; 8: 175-88.
112. Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997; 36: 419-28.
113. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-152.
114. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203.
115. Peroutka SJ. 5-Hydroxytryptamine receptors in vertebrates and invertebrates: why are there so many? Neurochem Int 1994; 25: 533-6.
116. Saudou F, Hen R. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem. Int 1994; 25: 503-32.
117. Turecki G. Suicidal behavior: is there a genetic predisposition? Bipolar Disord 2001; 3: 335-49.
118. Gaddum JH, Picarelli AP. Two kinds of tryptamine receptor. Br J Pharmacol 1957; 12: 323-28.
119. Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functinal receptors for 5-hydroxytryptamine. Neuropharmacology 1986; 25: 563-76.
120. 1A receptor. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp. 1301-1310, 1995.
121. Arango V, Ernsberger P, Marzuk PM, et al. Autoradiographic demonstration of increased serotonin 5-HT2 and β-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990; 47: 1038-47.
122. 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 2001; 25: 892-903.
123. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 1997; 16: 162-73.
124. 1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 1998; 18: 7394-401.
125. Lowther S, De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW. 5-HT1A receptor binding sites in postmortem brain samples from depressed suicides and controls. J Affect Disord 1997; 42: 199-207.
126. 1A binding sites in frontal cortex of suicide victims. Neural Trans Gen Sect 1991; 85: 181-94.
127. Dillon KA, Gross-Isseroff R, Israeli M, Biegon A. Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Res 554; 56-64: 1991.
128. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43: 954-9.
129. 2 receptor changes in major depression. Biol Psychiatry 1990; 27: 489-96.
130. Turecki G, Briere R, Dewar K, et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999; 156: 1456-8.
131. 2A receptors in the postmortem brain of teenage suicide victims. Am J Psychiatry 2002; 159: 419-29.
132. Lowther S, De Paermentier F, Crompton MR, Katona CL, Horton RW. Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment. Brain Res 1994; 642: 281-9.
133. Owen F, Cross AJ, Crow TJ, et al. Brain 5-HT-2 receptors and suicide. Lancet 1983; 2: 1256
134. McKeith IG, Marshall EF, Ferrier IN, et al. 5HT receptor binding in postmortem brain from patients with affective disorder. J Affect Disord 1997; 13: 67-74.
135. 2 receptor binding sites in depressed suicide victims. Brain Res 1988; 443: 272-80.
136. 3) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 2000; 99: 173-181.
137. 3H]ketanserin binding in the human brain postmortem: effect of suicide. Brain Res 1990; 507: 208-215.
138. Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and muopioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004; 29: 1512-21.
139. Giorgetti M, Tecott LH. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 2004; 488: 1-9.
140. Burns CM, Chu H, Rueter SM, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997; 387: 303-8.
141. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 1999; 274: 9472-8.
142. Wang Q, O'Brien PJ, Chen CX, Cho DS, Murray JM, Nishikura K. Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors. J Neurochem 2000; 74: 1290-300.
143. 3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol 1999; 10: 21-6.
144. Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 2001; 6: 373-9.
145. Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002; 34: 349-56.
146. Pandey GN, Dysken MW, Garver DL, Davis JM. Beta-adrenergic receptor function in affective illness. Am J Psychiatry 1979; 136: 675-78.
147. Pandey GN, Janicak PG, Davis JM. Decreased beta-adrenergic receptors in the leukocytes of depressed patients. Psychiatry Res 1987; 22: 265-73.
148. Mann JJ, Halper JP, Wilner PJ, et al. Subsensitivity of adenylyl cyclase-coupled receptors on mononuclear leukocytes from drug-free inpatients with a major depressive episode. Biol Psychiatry 1997; 42: 859-70.
149. Gurguis GN, Turkka J, Laruelle M, Kleinman J, Linnoila M. Coupling efficiency of brain beta-adrenergic receptors to Gs protein in suicide, alcoholism and control subjects. Psychopharmacology (Berl) 1999; 145: 31-8.
150. Srivastava N, Barthwal MK, Dalal PK, et al. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002; 72: 45-52.
151. Werstiuk ES, Steiner M, Burns T. Studies on leukocyte beta-adrenergic receptors in depression: a critical appraisal. Life Sci 1990; 47: 85-105.
152. Frazer A, Pandey G, Mendels J, Neeley S, Kane M, Hess ME. The effect of tri-iodothyronine in combination with impramine on [3H]-cyclic AMP production in slices of rat cerebral cortex. Neuropharmacology 1974; 13: 1311-40.
153. Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 1975; 257: 495-96.
154. Banerjee SP, Kung LS, Riggi SJ, Chanda. SK. Development of beta-adrenergic receptor subsensitivity by antidepressants. Nature 1976; 268: 455-6.
155. 3H]clonidine binding in the platelets of patients with depressive and schizophrenic disorders. Psychiatry Res 1989; 28: 73-88.
156. Garcia-Sevilla JA, Zis AP, Hollingsworth PJ, Greden JF, Smith CB. Platelet alpha 2-adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Arch Gen Psychiatry 1981; 38: 1327-33.
157. Pandey GN, Pandey SC. Peripheral markers of neurotransmitter dysfunction in affective illness. In: Khanna S, Channabasavanna SM, Keshavan MS. (Eds) Methods in biological psychiatry. McGraw-Hill Publishing Company, New Delhi 53-66, 1995.
158. Sugrue MF. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 1983; 21: 1-33
159. Frazer A, Conway P. Pharmacologic mechanisms of action of antidepressants. Psychiatr Clin North Am 1984; 7: 575-86.
160. Pilc A. The role of alpha 2-adrenoceptors in the mechanism of action of antidepressant drugs. Pol J Pharmacol Pharm 1987; 39: 691-713
161. Subhash MN, Nagaraja MR, Sharada S, Vinod KY. Cortical alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochem Int 2003; 43: 603-9.
162. DePaermentier F, Cheetham SC, Crompton MR, Katona CLE, Horton RW. Brain β-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment. Psychopharmacology 1991; 105: 283-8.
163. Little KY, Clark TB, Ranc J, Duncan GE. β-adrenergic receptor binding in frontal cortex from suicide victims. Biol Psychiatry 1993; 34: 596-605.
164. 3H]paraamino-clonidine binding to platelet adrenoreceptors in depression. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 541-53.
165. 2-adrenergic receptor sensitivity in major depressive disorders. Psychiatry Res 1983; 10: 157-64.
166. 3H]Rauwolscine binding in platelet from depressed patients and healthy volunteers. Psychopharmacology 1983; 79: 308-12.
167. 2-adrenoceptor binding sites in antidepressant-treated suicides and controls. Br J Pharmacol 199 1; 104: 275P.
168. 1-noradrenergic receptors in the human brain postmortem effect of suicide. Arch Gen Psychiatry 1990; 47: 1049-53.
169. 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J Neurochem 1994; 63: 617-24.
170. Ordway GA, Schenk J, Stockmeier CA, May W, Klimek V. Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry 2003; 53: 315-23.
171. Garcia-Sevilla JA, Escriba PV, Guimon J. Imidazoline receptors and human brain disorders. Ann N Y Acad Sci 1999; 881: 392-409.
172. Underwood MD, Mann JJ, Arango V. Serotonergic and noradrenergic neurobiology of alcoholic suicide. Alcohol Clin Exp Res 2004; 28(5 Suppl): 57S-69S.
173. 2 adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res 1993; 630: 271-82.
174. 35S]GTPgamma binding to G-proteins in postmortem brains of opioid addicts. Mol Psychiatry 2000; 5: 308-15.
175. Pacheco MA, Stockmeier C, Meltzer HY, Overholser JC, Dilley GE, Jope RS. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res 1996; 723: 37-45.
176. Dwivedi Y, Rizavi H, Shukla P, et al. Protein kinase A in postmortem brain of depressed suicide victims: Altered expression of specific regulatory and catalytic subunits. Biological Psychiatry 2004; 55: 234-243.
177. Sanders-Bush E. 5-HT receptors coupled to phosphoinositide hydrolisis. In: Sanders-Bush E, ed. The serotonin receptors. Clifton, NJ: Humana Press, 1988; pp. 181-198
178. Garro MA, Lopez de Jesus M, Ruiz de Azua I, Callado LF, Meana JJ, Salles J. Regulation of phospholipase Cbeta activity by muscarinic acetylcholine and 5HT(2) receptors in crude and synaptosomal membranes from human cerebral cortex. Neuropharmacology 2001; 40: 686-95.
179. Abdel-Latif AA. Calcium-mobilizing receptors, polyphosphoinositides, and the generation of second messengers. Pharmacol Rev 1986; 38: 227-71.
180. Berridge MJ, Irvine RF. Inositol phosphates and cell signaling. Nature 1989; 341: 197-205.
181. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-5.
182. Xie H, Rothstein TL. Protein kinase C mediates activation of nuclear cAMP response element-binding protein (CREB) in B lymphocytes stimulated through surface Ig. J Immunol 1995; 154: 1717-23.
183. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001; 78: 1219-32.
184. Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during
185. Dale, TC. Signal transduction by the Wnt family of ligands. Biochem J 1998; 329: 209-23.
186. Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell 1992; 71:713-6.
187. Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 1993; 268: 1501-4.
188. Aderem A. The MARCKS family of protein kinase-C substrates. Biochem Soc Trans 1995; 23: 587-91.
189. Allen L-H, Aderem. A. Protein kinase C regulates MARCKS cycling between the plasma membrane and lysozomes in fibroblasts. EMBO J 1995; 14: 1109-21.
190. Swierczynski SL, Blackshear PJ. Membrane association of the myristoylated alanine-rich C kinase substrate (MARCKS) protein. Mutational analysis provides evidence for complex interactions. J Biol Chem 1995; 270: 13436-45.
191. Rosen A, Keenan KF, Thelen M, Nairn AC, Aderem A. Activation of protein kinase C results in the displacement of its myristoylated, alanine-rich substrate from punctate structure in macrophage filopodia. J Exp Med 1990; 172: 1211-5.
192. Jackson SP. Regulating transcription factor activity by phosphorylation. Trends Cell Biol 1992; 2: 104-8.
193. Karin M, Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem Sci 1992; 17: 418-22.
194. Borrelli E, Montmayeur JP, Foulkes NS, Sassone-Corsi P. Signal transduction and gene control: the cAMP pathway. Crit Rev Oncog 1992; 3: 321-38.
195. Montminy MR, Gonzalez GA, Yamamoto KK. Regulation of cAMP-inducible genes by CREB. Trends Neurosci 1990; 13: 184-8.
196. Riabowol KT, Fink JS, Gilman MZ, Walsh DA, Goodman RH, Feramisco JR. The catalytic subunit of cAMP-dependent protein kinase induces expression of genes containing cAMP-responsive enhancer elements. Nature 1988; 336: 83-6.
197. Wang YC, Pandey GN, Mendels J, Frazer A. Platelet adenylate cyclase responses in depression: implications for a receptor defect. Psychopharmacologia 1974; 36: 291-300.
198. Extein I, Tallman J, Smith CC, Goodwin FK. Changes in lymphocyte beta-adrenergic receptors in depression and mania. Psychiatry Res 1979; 1: 191-7.
199. Gilman AG. Guanine nucleotide-binding regulatory proteins and dual control of adenylate cyclase; J Clin Invest 1984; 73: 1-4.
200. Gilman A.G. G proteins: transducers of receptor-generated signals. Ann Rev Biochem 1987; 56: 615-49.
201. Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995; 80: 240-57.
202. Clapham DE, Neer EJ. G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 1997; 37: 167-203.
203. Tamir J, Fawzi AB, Tamir A, Evans T, Northrup JK. G proteins βγ forms: identity of β and diversity of γ subunits. Biochemistry 1991; 30: 3919-26.
204. Simon MI, Strathman MP, Gautam N. Discovery of G proteins in signal transduction. Science 1991; 252: 802-8.
205. Birnbaumer L, Abramowitz J, Yatani A, et al. Roles of G proteins in coupling of receptors to ionic channels and other effector systems. Crit Rev Biochem Mol Biol 1990; 25: 225-44.
206. Kurose H, Regan JW, Caron MG, Letkowitz RJ. Functional interactions of recombinant alpha 2 adrenergic receptor subtypes and G proteins in reconstituted phospholipid vesicles. Biochemistry 1991; 30: 3335-41.
207. Fields TA, Casey PJ. Signaling functions and biochemical properties of pertussis toxin-resistant G-proteins. Biochem J 1997; 321: 561-71.
208. Brown NA, McAllister G, Weinberg D, Milligan G, Seabrook GR. Involvement of G-protein alpha subunits in activation of G-protein gated inward rectifying K+ channels (GIRK1) by human NPY1 receptors. Br J Pharmacol 1995; 116: 2346-8.
209. o protein as signal transducer in the pertussis toxin-sensitive phosphatidylinositol pathway. Nature 1990; 343: 79-82.
210. o. In: Iyengar, I, Birnbaumer, L, eds G Proteins New York, Academic Press; 81-113, 1990
211. i2 alpha subunit mRNA levels in rat cortex. Eur J Pharmacol Mol Pharmacol Sect 1991; 206: 165-6.
212. Lesch K-P, Manji HK. Signal transducing G proteins and antidepressant drugs: evidence for modulation of α subunit gene expression in rat brain. Biol Psychiatry 1992; 32: 549-79.
213. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry 1992; 149: 746-60.
214. 8 α protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 1993; 61: 890-5.
215. q-11 expression and hormone-stimulated phospholipase C activity in UMR-106-01 cells, Am. J. Physiol 1997; 273 Endocrinol Metab. 36: E528-E535.
216. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways: Molecular targets for lithium's action. Arch Gen Psychiatry 1995; 52: 531-43.
217. Avissar S, Nechamkin Y, Barki-Harrington L, Roitman G, Schreiber G. Differential G protein measures in mononuclear leukocytes of patients with bipolar mood disorder are state dependent. J Affect Disord 1997; 43: 85-93.
218. Cowburn RF, Marcusson JO, Eriksson A, Wiehager B, O'Neill C. Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res 1994; 633: 297-304.
219. Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT. G Protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem 1999; 73: 1121-6.
220. Garcia-Sevilla JA, Escriba PV, Ozaita A, et al. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999; 72: 282-91.
221. Gurguis GN, Turkka J, Laruelle M, Kleinman J, Linnoila M. Coupling efficiency of brain beta-adrenergic receptors to Gs protein in suicide, alcoholism and control subjects. Psychopharmacology (Berl) 1999; 145: 31-8.
222. Sastre M, Guimon J, Garcia-Sevilla JA. Relationships between beta- and alpha2-adrenoceptors and G coupling proteins in the human brain: effects of age and suicide. Brain Res 2001; 898: 242-55.
223. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. mRNA and protein expression of selective alpha subunits of G proteins are abnormal in prefrontal cortex of suicide victims. Neuropsychopharmacology 2002; 27:499-517.
224. 2A adrenoceptors. Mol Psychiatry 2002; 7: 755-67.
225. Joseph SK, Williamson JR. Inositol polyphosphates and intracellular calcium release. Arch Biochem Biophys 1989; 273: 1-15.
226. Cockcroft S, Thomas GM. Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors. Biochem J 1992; 288: 1-14.
227. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001; 70: 281-312.
228. Banno Y, Nozawa Y. Characterization of partially purified phospholipase C from human platelet membranes. J Biochem 1987; 248: 95-101.
229. Lee K-Y, Ryu SH, Suh P-G, Choi WC, Rhee S.G. Phospholipase C associated with particulate fractions of bovine brain. Biochem. 1987; 84:5540-4.
230. Anderson D, Koch CA, Grey L, Ellis C, Moran MF, Pawson T. Binding of SH2 domains of phospholipase C 1, GAP, and Src to activated growth factor receptors. Science 1990; 250: 979-82.
231. D. Regulation of inositol phospholipid-specific phospholipase C isozymes. J Biol Chem 1992; 267:12393-6.
232. Exton JH. Phosphoinositide phospholipases and G proteins in hormone action. Ann Rev Physio 1994; 56: 349-69.
233. q class of G proteins. Nature 1991; 350: 516-8.
234. Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem 1997; 272: 15045-8.
235. 1 protein in the PFC of teenage suicide subjects. Am J Psychiatry 1999; 156: 1895-901.
236. Tanaka C, Nishizuka Y. The protein kinase C family for neuronal signaling. Annu Rev Neurosci 1994; 17: 551-67.
237. Sherman MS, Naor Z, Kikkawa U, Nishizuka Y. Differential expression of multiple protein kinase C subspecies in rat central nervous tissue. Biochem Biophys Res Comm 1988; 147: 911-9.
238. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-96.
239. Newton AC. Protein Kinase C: structure, function, and regulation. J Biol Chem 1995; 270: 28495-8.
240. Stable S, Parker PJ. Protein kinase C. Pharmacol Ther 1991; 51:71-95.
241. Jaken S, Kiley SC. Protein kinase C: interactions and consequences. Trends Cell Biol 1994; 4: 223-7.
242. Hug H, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 1993; 291: 329-43.
243. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-13.
244. Akimoto K, Mizuno K, Osada S, et al. A new member of the third class in the protein kinase C family, PKCG1, expressed dominantly in an undifferentiated mouse embryonal carcinoma cell line and also in many tissues and cells. J Biol Chem 1994; 269: 12677-83.
245. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. Protein kinase N subspecies from rat brain: its structure, expression and properties. Proc Natl Acad Sci USA 1989; 86: 3099-103.
246. Ono Y, Fujii T, Ogita Y, Kikkawa U, Igarashi Y, Nishizuka Y. The structure, expression and properties of additional members of protein kinase C family. J Biol Chem 1988; 263: 6927-32.
247. Grabarek J, Raychowdhury M, Ravid K, Kent KC, Newman PJ, Ware JA. Identification and functional characterization of protein kinase C isozymes in platelets and HELA cells. J Biol Chem 1992; 267: 10011-7.
248. Baldassare JJ, Henderson PA, Burn D Loomis C, Fisher GT. Transduction of protein kinase C isozymes in thrombin-stimulated human platelets. J Biol Chem 1992; 267: 15585-90.
249. Kaczmarek L.K. The role of protein kinase C in the regulation of ion channels and neurotransmitter release. Trends Neurosci 1987; 10: 30-4.
250. Nichols M, Weih F, Schmid W, et al. Phosphorylation of CREB affects its binding to high and low affinity sites: implication for cAMP-induced gene transcription. EMBO J 1992; 11: 3337-46.
251. Friedman E, Hoau Yan-Wang, Levinson D, Connell TA, Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993; 33: 520-5.
252. Manji HK, Etcheberrigaray R, Chen G, Olds JL. Lithium decreases membrane-associated protein kinase C in hippocampus: Selectivity for the alpha isozyme. J Neurochem 1993; 61: 2303-10.
253. Mann CD, Vu TB, Hrdina PD. Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. Br J Pharmacol 1995; 115: 595-600.
254. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. Modulations in CNS signal transduction pathways and gene expression by mood stabilizing agents: therapeutic implications. J Clin Psychiatry 1999; 60: 27-39.
255. Pandey GN, Dwivedi Y, SridharaRao J, Ren X, Janicak PG, Sharma R. Protein kinase C and phospholipase C activity and expression of their specific isozymes is decreased and expression of MARCKS is increased in platelets of bipolar but not in unipolar patients. Neuropsychopharmacol 2002; 26: 216-28.
256. Dean B, Opeskin K, Pavey G, Hill C, Keks N. Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia. J Neural Transm 1997; 104: 1371-81.
257. Cole G, Dobkins KR, Hansen LA, Terry RD, Saitoh T. Decreased levels of protein kinase C in Alzheimer brain. Brain Res 1988; 452: 165-74.
258. Stokes CE, Hawthorne JN. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J Neurochem 1987; 48: 1018-21.
259. Masliah E, Cole G, Shimohama S, et al. Differential involvement of protein kinase C isozymes in Alzheimer's disease. J Neurosci 1990; 10: 2113-24.
260. Shimohama S, Narita M, Matsushima H, et al. Assessment of protein kinase C isozyme by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. Neurology 1993; 43: 1407-13.
261. Coull MA, Lowther S, Katona CL, Horton RW. Altered brain protein kinase C in depression: a post-mortem study. Eur Neuropsychopharmacol 2000; 10:283-8.
262. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48: 740-54.
263. Lenox RH, Watson DG, Patel J, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992; 570: 333-40.
264. Watson DG, Wainer BH, Lenox RH. Phorbol ester- and retinoic acid-induced regulation of the protein kinase C substrate MARCKS in immortalized hippocampal cells. J Neurochem 1994; 63:1666-74.
265. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: Potentiation by muscarinic receptor activation. J Neurochem 1996; 67: 767-77.
266. Wang L, Watson DG, Lenox RH. Myristoylation alters retinoic acid-induced down-regulation of MARCKS in immortalized hippocampal cells. Biochem Biophys Res Commun 2000; 276: 183-8.
267. Yamauchi E, Kiyonami R, Kanai M, Taniguchi H. The C-terminal conserved domain of MARCKS is phosphorylated in vivo by proline-directed protein kinase. Application of ion trap mass spectrometry to the determination of protein phosphorylation sites. J Biol Chem 1998; 273: 4367-71.
268. Kim J, Shishido T, Jiang X, Aderem A, McLaughlin S. Phosphorylation, high ionic strength, and calmodulin reverse the binding of MARCKS to phospholipid vesicles. J Biol Chem 1994; 269: 28214-9.
269. Heemskerk FM, Chen HC, Huang FL. Protein kinase C phosphorylates Ser152, Ser156, and Ser158 but not Ser160 of MARCKS in rat brain. Biochem Biophys Res Commun 1993; 190: 236-41.
270. Fujise A, Mizuno K, Udea Y, et al. Specificity of the high affinity interaction of protein kinase C with physiological substrate myristoylated alanine-rich protein kinase C substrate. J Biol Chem 1994; 269: 31642-8.
271. Sheu FS, Huang FL, Huang KP. Differential responses of protein kinase C substrates (MARCKS neuromodulin, and neurogranin) phosphorylation to calmodulin and S-100. Arch Biochem Biophys 1995; 316: 333-342.
272. Ouimet CC, Wang JK, Walaas SI, Albert KA, Greengard P. Localization of the MARCKS (87 kDa) protein, a major specific substrate for protein kinase C, in rat brain. J Neurosci 1990; 10:1683-98.
273. Erusalimsky JD, Brooks SF, Herget T, Morris C, Rozengurt E. Molecular cloning characterization of the acidic 80-kDa protein kinase C substrate from rat brain. J Biol Chem 1991; 266: 7073-80.
274. Harlan DM, Graff JM, Stumpo DJ, et al. The human myristoylated alanine-rich C kinase substrate (MARCKS) gene (MACS). Analysis of its gene product, promoter, and chromosomal localization. J Biol Chem 1991; 266: 14399-405.
275. Rodriguez-Pena A, Zachary I, Rozengurt E. Rapid dephosphorylation of an Mr 80000 protein, specific substrate of protein kinase C upon removal of phorbol ester, bombesin and vasopressin. Biochem Biophys Res Commun 1986; 140: 379-85.
276. Wang JKT, Walaas SI, Greengard P. Protein phosphorylation in nerve terminals: comparison of calcium/calmodulin-dependent and calcium/ diacylglycerol-dependent systems J Neurosci 1988; 8: 281-8.
277. McNamara RK, Hyde TM, Kleinman JE, Lenox RH. Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. J Clin Psychiatry 1999; 60 suppl 2:21-6.
278. Pandey GN, Dwivedi Y, Ren X, et al. Altered expression and phosphorylation of myristoylated alanine-reich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. J Psychiatr Res 2003; 37: 421-32.
279. Skiålhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci 2000; 5: D678-693.
280. Nestler EJ, Greengard P. Protein phosphorylation and the regulation of neuronal function, in Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. Little, Brown, Boston, 449-474, 1994.
281. Popoli M, Brunello N, Perez J, Racagni G. Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J Neurochem 2000; 74: 21-33.
282. Popoli M, Mori S, Brunello N, Perez J, Gennarelli M, Racagni G. Serine/ threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders. Pharmacol Ther 2001; 89:149-70.
283. 3H]cAMP binding sites are unaltered in depressed suicides, but decreased by antidepressants. Brain Res 1997; 758: 223-8
284. Reiach JS, Li PP, Warsh JJ, Kish SJ, Young LT. Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims. J Affect Disord 1999; 56: 141-51.
285. Odagaki Y, Garcia-Sevilla JA, Huguelet P, La Harpe R, Koyama T, Guimon J. Cyclic AMP-mediated signaling components are upregulated in the prefrontal cortex of depressed suicide victims. Brain Res 2001; 898: 224-31.
286. Shelton RC, Mainer DH, Sulser F. cAMP-dependent protein kinase activity in major depression. Am J Psychiatry 1996; 153: 1037-42.
287. Shelton RC, Manier DH, Peterson CS, Ellis TC, Sulser F. Cyclic AMP-dependent protein kinase in subtypes of major depression and normal volunteers. Int J Neuropsychopharmacol 1999; 2:187-92.
288. 3H] cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem 1997; 68: 297-304.
289. Fields A, Li PP, Kish SJ, Warsh JJ. Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. J Neurochem 1999; 73:1704-10.
290. Chang A, Li PP, Warsh JJ. Altered cAMP-dependent protein kinase A subunit immunolabeling in postmortem brain from patients with bipolar affective disorder. J. Neurochem 2003; 84: 781-91.
291. Perez J, Tardito D, Racagni G, Smeraldi E, Zanardi R. Protein kinase A and Rap1 levels in platelets of untreated patients with major depression. Mol Psychiatry 2001; 6: 44-9.
292. 3H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. Am J Psychiatry. 2002; 159: 66-73.
293. Pandey GN, Dwivedi Y, Ren X, et al. Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. Neuropsychopharmacology 2005 (In Press).
294. Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet. 1998 352: 1754-5.
295. Dwivedi Y, Rao JS, Rizavi HS, et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 273-82.
296. Brandon EP, Logue SF, Adams MR, et al. Defective motor behavior and neural gene expression in RIIβ-protein kinase A mutant mice. J Neurosci 1998; 18: 3639-49.
297. Holian O, Kumar R, Attar B. Apoprotein A-1 is a cofactor independent substrate of protein kinase C. Biochem Biophys Res Commun 1991; 179: 599-604.
298. Moore AN, Waxham, MN, Dash PK. Neuronal activity increases the phosphorylation of the transcription factor cyclic AMP response element binding protein (CREB) in rat hippocampus and cortex. J Biol Chem 1996; 271: 14214-20.
299. Imaki J, Yoshida K, Yamashita K. A developmental study of cyclic AMP-response element binding protein (CREB) by in situ hybridization histochemistry and immunochemistry in the rat neocortex. Brain Res 1994; 651: 269-74.
300. Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu Rev Neurosci 1998; 21: 127-48.
301. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-72.
302. Yamada S, Yamamoto M, Ozawa H, Piederer P, Saito T. Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm 2003; 110: 671-80.
303. Finkbeiner S. Calcium regulation of the brain-derived neurotrophic factor gene. Cell Mol Life Sci 2000; 57: 394-401.
304. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development function. Annu Rev Neurosci 2001; 24: 677-736.
305. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270: 593-8.
306. Altar CA, Cai N, Bliven T, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856-60.
307. Bartrup JT, Moorman JM, Newberry NR. BDNF enhances neuronal growth and synaptic activity in hippocampal cell cultures. Neuroreport 1997; 8: 3791-4.
308. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-47.
309. Sapolsky RM. Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. Stress 1996; 1: 1-19.
310. Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology 1999; 21: 474-84.
311. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci 1999; 22:105-22.
312. Smith MA, Makino S, Kvetnansky R, Post RM. Effects of stress on neurotrophic factor expression in the rat brain. Ann. NY Acad Sci 1995; 771: 234-39.
313. Ueyama T, Kawai Y, Nemoto K, Sekimoto M, Tone S, Senba E. Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain. Neurosci Res 1997; 28:103-10.
314. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 1999; 89: 157-66.
315. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997; 154: 1497-503.
316. Lauterborn JC, Poulsen FR, Stinis CT, Isackson PJ, Gall CM. Transcript-specific effects of adrenalectomy on seizure-induced BDNF expression in rat hippocampus. Brain Res Mol Brain Res 1998; 55: 81-91.
317. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804-15.
318. Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol 1994; 25: 1386-403.
319. Dechant G, Rodriguez-Tebar A, Barde YA. Neurotrophin receptors. Prog Neurobiol 1994; 42: 347-52.
320. Middlemas DS, Lindberg RA, Hunter T. trkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 1991; 11: 143-53.
321. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265.